The implications for resource uti- lization for standardized of ce BP measurement, as recom- mended in this guideline, are discussed in Chapter 1. Costs of additional antihypertensive drugs are relatively small in view of the bene ts; however, there may be additional costs for monitoring. The Work Group does not consider that resource implications would have signi cant impact on the recom- mendation. Indeed, economic analysis using SPRINT data suggest that intensive SBP treatment is cost-effective.154 Nonetheless, it is possible that there will be dif culties in implementing these recommendations in countries in which resources are limited; in those settings, it is probably more important to ensure that all eligible patients have at least reasonable BP control (e.g., SBP <140 mm Hg) than to focus efforts on achieving intensive BP control in a smaller fraction of the population. Considerations for implementation. Although there is strong evidence that home BP measurements are predictive of long- term adverse clinical outcomes, no adequately powered trial for guiding antihypertensive medication based on home BP targets has been reported. Nonetheless, HBPM may help to improve patient motivation and adherence to treatment and can also be used to identify patients with masked hypertension, masked uncontrolled hypertension, white- coat hypertension, and the white-coat effect as an adjunct for diagnosis and potential management of BP (see Chapter 1). The use of standardized of ce measurements for BP management may require additional equipment, clinic space, time, training, and/or change in culture, habits, or policies (see Chapter 1). Practitioners would bene t from under- standing the guidelines and the underlying data and rationale, and can tailor the target and treatment strategy for individual patients according to overall health conditions, response and tolerability to SBP lowering, as well as their preferences. Shared decision-making with individual patients is essential. 